栾雪，博士，讲师，1992年生，本科、硕士毕业于江南大学和吉林大学，2022年12月博士毕业于吉林大学。2022年加入徐州医科大学第一临床医院肿瘤生物治疗实验室。目前从事消化系统肿瘤发生发展机制研究，先后在Pharmaceuticals、Molecules、EuropeanJournal of Pharmaceutics and Biopharmaceutics、Glycoconjugate Journal等刊物以第一作者身份发表SCI论文4篇。

PUBLICATIONS：

1.LuanXue, Sun Ming, Zhao Xue. Bisimidazolium salt glycosyltransferase inhibitors suppress hepatocellular carcinoma progression in vitro and in vivo [J].Pharmaceuticals, 2022, 15:716-742.

2.LuanXue^#, Cong Zhongcheng^#, Tassos P. Anastassiades.N-Butyrylated hyaluronic acid achieves anti-inflammatory effects in vitro and in adjuvant-induced immune activation in rats [J].Molecules, 2022, 10: 3267-3281.

3.Bai Ruifeng^#,Luan Xue^#, Zhang Yu. The expression and functional analysis of the sialyl-T antigen in prostate cancer.Glycoconjugate Journal, 2020, 37:423-433.

4.LuanXue, Kamil Rahme, Cong Zhongcheng. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice [J].European Journal of Pharmaceutics and Biopharmaceutics, 2019, 137:56-67.